Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 4/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25710413 | 0.78 | SYK (0.35) | SYKZAP70MKNK1MKNK2CDK1 | |
| SCHEMBL25712246 | 0.75 | PDE10A (0.38) | MAPK10CDK1AURKBPDE10A | |
| SCHEMBL24054153 | 0.73 | SMN1; SMN2 (0.49) | MAPK10PDE10A | |
| SCHEMBL24584789 | 0.68 | FERMT2 (0.40) | SYKZAP70CXCR4CDK1STK17A | |
| SCHEMBL25710641 | 0.67 | BRD4 (0.40) | STK17AITK | |
| SCHEMBL25695340 | 0.67 | KDM4E (0.47) | PDE10A | |
| SCHEMBL14983704 | 0.66 | STK17A (0.48) | SYKZAP70CXCR4STK17AKCNH2 | |
| SCHEMBL25284926 | 0.65 | KDM4E (0.45) | PDE10A | |
| SCHEMBL30166472 | 0.65 | KDM4E (0.45) | PDE10A | |
| SCHEMBL25075278 | 0.64 | SYK (0.46) | SYKZAP70CXCR4CDK1STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2021233397-A1 | PIPERAZINE CYCLIC UREAS | Sironax Ltd. (KY) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | SYK 3875/4885ZAP70 1566/4885MKNK1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.